{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:55:49Z","timestamp":1790142949686,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Union and the European Regional Development Fund","award":["GINOP-2.3.2-15-2016-00043"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00043"]}]},{"name":"European Union and the European Regional Development Fund","award":["GINOP-2.3.2-15-2016-00050"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00050"]}]},{"name":"National Research, Development and Innovation Fund of Hungary","award":["FK 128809"],"award-info":[{"award-number":["FK 128809"]}]},{"name":"National Research, Development and Innovation Fund of Hungary","award":["K134939"],"award-info":[{"award-number":["K134939"]}]},{"name":"National Research, Development and Innovation Fund of Hungary","award":["K 116940 and K 132623"],"award-info":[{"award-number":["K 116940 and K 132623"]}]},{"name":"National Research, Development and Innovation Fund of Hungary","award":["NVKP_16-1\u20132016-0017 (\u2019National Heart Program\u2019"],"award-info":[{"award-number":["NVKP_16-1\u20132016-0017 (\u2019National Heart Program\u2019"]}]},{"name":"National Research, Development and Innovation Fund of Hungary","award":["TKP2020-NKA-04"],"award-info":[{"award-number":["TKP2020-NKA-04"]}]},{"name":"Ministry for Innovation and Technology in Hungary","award":["Thematic Excellence Programme (2020-4.1.1.-TKP2020), Therapeutic Development and Bioimaging thematic programmes of the Semmelweis University"],"award-info":[{"award-number":["Thematic Excellence Programme (2020-4.1.1.-TKP2020), Therapeutic Development and Bioimaging thematic programmes of the Semmelweis University"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Angiotensin-converting enzyme 2 (ACE2) is essential for SARS-CoV-2 cellular entry. Here we studied the effects of common comorbidities in severe COVID-19 on ACE2 expression. ACE2 levels (by enzyme activity and ELISA measurements) were determined in human serum, heart and lung samples from patients with hypertension (<jats:italic>n<\/jats:italic>\u2009=\u2009540), heart transplantation (289) and thoracic surgery (<jats:italic>n<\/jats:italic>\u2009=\u200949). Healthy individuals (<jats:italic>n<\/jats:italic>\u2009=\u200946) represented the controls. Serum ACE2 activity was increased in hypertensive subjects (132%) and substantially elevated in end-stage heart failure patients (689%) and showed a strong negative correlation with the left ventricular ejection fraction. Serum ACE2 activity was higher in male (147%), overweight (122%), obese (126%) and elderly (115%) hypertensive patients. Primary lung cancer resulted in higher circulating ACE2 activity, without affecting ACE2 levels in the surrounding lung tissue. Male sex resulted in elevated serum ACE2 activities in patients with heart transplantation or thoracic surgery (146% and 150%, respectively). Left ventricular (tissular) ACE2 activity was unaffected by sex and was lower in overweight (67%), obese (62%) and older (73%) patients with end-stage heart failure. There was no correlation between serum and tissular (left ventricular or lung) ACE2 activities. Neither serum nor tissue (left ventricle or lung) ACE2 levels were affected by RAS inhibitory medications. Abandoning of ACEi treatment (non-compliance) resulted in elevated blood pressure without effects on circulating ACE2 activities. ACE2 levels associate with the severity of cardiovascular diseases, suggestive for a role of ACE2 in the pathomechanisms of cardiovascular diseases and providing a potential explanation for the higher mortality of COVID-19 among cardiovascular patients. Abandoning RAS inhibitory medication worsens the cardiovascular status without affecting circulating or tissue ACE2 levels.<\/jats:p>","DOI":"10.1007\/s11357-021-00467-2","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T09:02:41Z","timestamp":1634806961000},"page":"2289-2304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients"],"prefix":"10.1007","volume":"43","author":[{"given":"Mikl\u00f3s","family":"Fagyas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"B\u00e1nhegyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"\u00dari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Enyedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erzs\u00e9bet","family":"Lizanecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivetta Siket","family":"M\u00e1nyin\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilla","family":"M\u00e1rtha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor \u00c1ron","family":"F\u00fcl\u00f6p","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Radovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"P\u00f3los","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Merkely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Szilv\u00e1ssy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Ungv\u00e1ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"\u00c9des","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Csan\u00e1di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Bocz\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Tak\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3zsef","family":"Balla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Balla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Seferovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6503-3653","authenticated-orcid":false,"given":"Attila","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"467_CR1","unstructured":"Coronavirus Resource Center, Johns Hopkins University. https:\/\/coronavirus.jhu.edu\/map.html. Accessed 7 May 202."},{"key":"467_CR2","doi-asserted-by":"publisher","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020. https:\/\/doi.org\/10.1016\/s2213-2600(20)30116-8.","DOI":"10.1016\/s2213-2600(20)30116-8"},{"key":"467_CR3","doi-asserted-by":"publisher","unstructured":"Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020. https:\/\/doi.org\/10.1016\/s2213-2600(20)30079-5.","DOI":"10.1016\/s2213-2600(20)30079-5"},{"key":"467_CR4","doi-asserted-by":"publisher","unstructured":"Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. https:\/\/doi.org\/10.1111\/all.14238.","DOI":"10.1111\/all.14238"},{"issue":"4","key":"467_CR5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41371-020-00451-x","volume":"35","author":"CE Clark","year":"2021","unstructured":"Clark CE, McDonagh STJ, McManus RJ, Martin U. COVID-19 and hypertension: risks and management. A scientific statement on behalf of the British and Irish hypertension society. J Hum Hypertens. 2021;35(4):304\u20137. https:\/\/doi.org\/10.1038\/s41371-020-00451-x.","journal-title":"J Hum Hypertens"},{"issue":"7","key":"467_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","volume":"5","author":"T Guo","year":"2020","unstructured":"Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2020.1017.","journal-title":"JAMA Cardiol"},{"key":"467_CR7","doi-asserted-by":"publisher","unstructured":"Linschoten, Asselbergs FW. CAPACITY-COVID: a European registry to determine the role of cardiovascular disease in the COVID-19 pandemic. Eur Heart J. 2020. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa280.","DOI":"10.1093\/eurheartj\/ehaa280"},{"key":"467_CR8","doi-asserted-by":"publisher","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052.","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"467_CR9","doi-asserted-by":"publisher","unstructured":"Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020. https:\/\/doi.org\/10.1016\/j.cell.2020.02.058.","DOI":"10.1016\/j.cell.2020.02.058"},{"issue":"3","key":"467_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/shk.0000000000000633","volume":"46","author":"H Jia","year":"2016","unstructured":"Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock. 2016;46(3):239\u201348. https:\/\/doi.org\/10.1097\/shk.0000000000000633.","journal-title":"Shock."},{"issue":"4","key":"467_CR11","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"H Zhang","year":"2020","unstructured":"Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586\u201390.","journal-title":"Intensive Care Med"},{"key":"467_CR12","doi-asserted-by":"publisher","unstructured":"Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020. https:\/\/doi.org\/10.1002\/ddr.21656.","DOI":"10.1002\/ddr.21656"},{"key":"467_CR13","doi-asserted-by":"crossref","unstructured":"Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom. European Centre for Disease Prevention and Control, Stockholm. 2020. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/SARS-CoV-2-variant-multiple-spike-protein-mutations-United-Kingdom.pdf. Accessed 20 Dec\u00a02020.","DOI":"10.23880\/OAJPRS-16000132"},{"key":"467_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ijid.2020.11.184","volume":"103","author":"B Nagy","year":"2021","unstructured":"Nagy B, Fejes Z, Szentkereszty Z, S\u00fct\u0151 R, V\u00e1rkonyi I, Ajzner \u00c9, et al. A dramatic rise in serum ACE2 activity in a critically ill COVID-19 patient. Int J Infect Dis. 2021;103:412\u20134. https:\/\/doi.org\/10.1016\/j.ijid.2020.11.184.","journal-title":"Int J Infect Dis"},{"issue":"9","key":"467_CR15","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1164\/rccm.202101-0142LE","volume":"203","author":"R Reindl-Schwaighofer","year":"2021","unstructured":"Reindl-Schwaighofer R, Hodlmoser S, Eskandary F, Poglitsch M, Bonderman D, Strassl R, et al. ACE2 elevation in severe COVID-19. Am J Respir Crit Care Med. 2021;203(9):1191\u20136. https:\/\/doi.org\/10.1164\/rccm.202101-0142LE.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8 Suppl B","key":"467_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.18553\/jmcp.2007.13.s8-b.9","volume":"13","author":"SA Atlas","year":"2007","unstructured":"Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(8 Suppl B):9\u201320. https:\/\/doi.org\/10.18553\/jmcp.2007.13.s8-b.9.","journal-title":"J Manag Care Pharm"},{"key":"467_CR17","doi-asserted-by":"publisher","unstructured":"Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens. 2020;Publish Ahead of Print. https:\/\/doi.org\/10.1097\/hjh.0000000000002450.","DOI":"10.1097\/hjh.0000000000002450"},{"key":"467_CR18","doi-asserted-by":"publisher","unstructured":"Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020. https:\/\/doi.org\/10.1038\/s41569-020-0360-5.","DOI":"10.1038\/s41569-020-0360-5"},{"key":"467_CR19","doi-asserted-by":"publisher","unstructured":"Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMsr2005760.","DOI":"10.1056\/NEJMsr2005760"},{"key":"467_CR20","doi-asserted-by":"publisher","unstructured":"Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa235.","DOI":"10.1093\/eurheartj\/ehaa235"},{"issue":"20","key":"467_CR21","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/circulationaha.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605\u201310. https:\/\/doi.org\/10.1161\/circulationaha.104.510461.","journal-title":"Circulation."},{"issue":"5","key":"467_CR22","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","volume":"43","author":"Y Ishiyama","year":"2004","unstructured":"Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43(5):970\u20136. https:\/\/doi.org\/10.1161\/01.HYP.0000124667.34652.1a.","journal-title":"Hypertension."},{"key":"467_CR23","unstructured":"Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. European Society of Cardiology. 2020. https:\/\/www.escardio.org\/Councils\/Council-on-Hypertension-(CHT)\/News\/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. Accessed 19 Mar\u00a02020."},{"key":"467_CR24","unstructured":"Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. American Heart Association. 2020. https:\/\/newsroom.heart.org\/news\/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician. Accessed 19 Mar\u00a02020."},{"key":"467_CR25","doi-asserted-by":"publisher","unstructured":"Kreutz R, Algharably EAE, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020. https:\/\/doi.org\/10.1093\/cvr\/cvaa097.","DOI":"10.1093\/cvr\/cvaa097"},{"issue":"1","key":"467_CR26","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1186\/s12889-020-09826-8","volume":"20","author":"ND Yanez","year":"2020","unstructured":"Yanez ND, Weiss NS, Romand JA, Treggiari MM. COVID-19 mortality risk for older men and women. BMC Public Health. 2020;20(1):1742. https:\/\/doi.org\/10.1186\/s12889-020-09826-8.","journal-title":"BMC Public Health"},{"issue":"1","key":"467_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12933-020-01141-1","volume":"19","author":"AA Sayour","year":"2020","unstructured":"Sayour AA, Ol\u00e1h A, Ruppert M, Barta BA, Horv\u00e1th EM, Benke K, et al. Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure. Cardiovasc Diabetol. 2020;19(1):159. https:\/\/doi.org\/10.1186\/s12933-020-01141-1.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"467_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1470320316668435","volume":"17","author":"K Uri","year":"2016","unstructured":"Uri K, Fagyas M, Kertesz A, Borbely A, Jenei C, Bene O, et al. Circulating ACE2 activity correlates with cardiovascular disease development. J Renin-Angiotensin-Aldosterone Syst. 2016;17(4):1\u201311. https:\/\/doi.org\/10.1177\/1470320316668435.","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"issue":"4","key":"467_CR29","doi-asserted-by":"publisher","first-page":"e87845","DOI":"10.1371\/journal.pone.0087845","volume":"9","author":"K Uri","year":"2014","unstructured":"Uri K, Fagyas M, Manyine Siket I, Kertesz A, Csanadi Z, Sandorfi G, et al. New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure. PLoS One. 2014;9(4):e87845. https:\/\/doi.org\/10.1371\/journal.pone.0087845.","journal-title":"PLoS One"},{"issue":"4","key":"467_CR30","doi-asserted-by":"publisher","first-page":"e87843","DOI":"10.1371\/journal.pone.0087843","volume":"9","author":"M Fagyas","year":"2014","unstructured":"Fagyas M, Uri K, Siket IM, Darago A, Boczan J, Banyai E, et al. New perspectives in the renin-angiotensin-aldosterone system (RAAS) I: endogenous angiotensin converting enzyme (ACE) inhibition. PLoS One. 2014;9(4):e87843.","journal-title":"PLoS One"},{"issue":"4","key":"467_CR31","doi-asserted-by":"publisher","first-page":"e87844","DOI":"10.1371\/journal.pone.0087844","volume":"9","author":"M Fagyas","year":"2014","unstructured":"Fagyas M, Uri K, Siket IM, Fulop GA, Csato V, Darago A, et al. New perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin suppresses angiotensin converting enzyme (ACE) activity in human. PLoS One. 2014;9(4):e87844.","journal-title":"PLoS One"},{"key":"467_CR32","volume-title":"inventors; University of Debrecen, assignee","author":"A T\u00f3th","year":"2012","unstructured":"T\u00f3th A, Fagyas M, Papp Z, \u00c9des I. inventors; University of Debrecen, assignee. Hungary: Dilution based inhibition assay; 2012."},{"key":"467_CR33","doi-asserted-by":"publisher","unstructured":"Luan J, Jin X, Lu Y, Zhang L. SARS-CoV-2 spike protein favors ACE2 from Bovidae and Cricetidae. J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.25817.","DOI":"10.1002\/jmv.25817"},{"key":"467_CR34","doi-asserted-by":"publisher","unstructured":"Wallentin L, Lindb\u00e4ck J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, et al. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa697.","DOI":"10.1093\/eurheartj\/ehaa697"},{"issue":"19","key":"467_CR35","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/eurheartj\/ehaa373","volume":"41","author":"IE Sama","year":"2020","unstructured":"Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, Cleland JGF, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J. 2020;41(19):1810\u20137. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa373.","journal-title":"Eur Heart J"},{"issue":"4","key":"467_CR36","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G, Bj\u00f6rkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014;9(4):e95192. https:\/\/doi.org\/10.1371\/journal.pone.0095192.","journal-title":"PLoS One"},{"issue":"6891","key":"467_CR37","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nature00786","volume":"417","author":"MA Crackower","year":"2002","unstructured":"Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417(6891):822\u20138. https:\/\/doi.org\/10.1038\/nature00786.","journal-title":"Nature."},{"issue":"8","key":"467_CR38","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1172\/JCI16980","volume":"116","author":"SB Gurley","year":"2006","unstructured":"Gurley SB, Allred A, Le TH, Griffiths R, Mao L, Philip N, et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest. 2006;116(8):2218\u201325. https:\/\/doi.org\/10.1172\/JCI16980.","journal-title":"J Clin Invest"},{"issue":"1","key":"467_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11357-020-00300-2","volume":"43","author":"M Fagyas","year":"2021","unstructured":"Fagyas M, Kert\u00e9sz A, Siket IM, B\u00e1nhegyi V, Kracsk\u00f3 B, Szegedi A, et al. Level of the SARS-CoV-2 receptor ACE2 activity is highly elevated in old-aged patients with aortic stenosis: implications for ACE2 as a biomarker for the severity of COVID-19. GeroScience. 2021;43(1):19\u201329. https:\/\/doi.org\/10.1007\/s11357-020-00300-2.","journal-title":"GeroScience."},{"key":"467_CR40","doi-asserted-by":"publisher","unstructured":"Nicin L, Abplanalp WT, Mellentin H, Kattih B, Tombor L, John D, et al. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Eur Heart J. 2020. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa311.","DOI":"10.1093\/eurheartj\/ehaa311"},{"issue":"11","key":"467_CR41","doi-asserted-by":"publisher","first-page":"H1671","DOI":"10.1152\/ajpheart.00842.2015","volume":"310","author":"\u00c1 Kov\u00e1cs","year":"2016","unstructured":"Kov\u00e1cs \u00c1, F\u00fcl\u00f6p G\u00c1, Kov\u00e1cs A, Cs\u00edp\u0151 T, B\u00f3di B, Priksz D, et al. Renin overexpression leads to increased titin-based stiffness contributing to diastolic dysfunction in hypertensive mRen2 rats. Am J Phys Heart Circ Phys. 2016;310(11):H1671\u2013H82. https:\/\/doi.org\/10.1152\/ajpheart.00842.2015.","journal-title":"Am J Phys Heart Circ Phys"},{"issue":"1","key":"467_CR42","doi-asserted-by":"publisher","first-page":"L84","DOI":"10.1152\/ajplung.00071.2009","volume":"297","author":"HP Jia","year":"2009","unstructured":"Jia HP, Look DC, Tan P, Shi L, Hickey M, Gakhar L, et al. Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am J Phys Lung Cell Mol Phys. 2009;297(1):L84\u201396. https:\/\/doi.org\/10.1152\/ajplung.00071.2009.","journal-title":"Am J Phys Lung Cell Mol Phys"},{"issue":"5","key":"467_CR43","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.119.13133","volume":"74","author":"S Mukerjee","year":"2019","unstructured":"Mukerjee S, Gao H, Xu J, Sato R, Zsombok A, Lazartigues E. ACE2 and ADAM17 interaction regulates the activity of Presympathetic neurons. Hypertension. 2019;74(5):1181\u201391. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13133.","journal-title":"Hypertension."},{"issue":"S1","key":"467_CR44","doi-asserted-by":"publisher","first-page":"997.1","DOI":"10.1096\/fasebj.29.1_supplement.997.1","volume":"29","author":"H Chodavarapu","year":"2015","unstructured":"Chodavarapu H, Pedersen K, Lazartigues E. The ACE2 sheddase, ADAM17, is up-regulated in diabetic db\/db mice. FASEB J. 2015;29(S1):997.1. https:\/\/doi.org\/10.1096\/fasebj.29.1_supplement.997.1.","journal-title":"FASEB J"},{"key":"467_CR45","doi-asserted-by":"publisher","first-page":"104428","DOI":"10.1016\/j.meegid.2020.104428","volume":"85","author":"L Zhang","year":"2020","unstructured":"Zhang L, Han X, Shi Y. Comparative analysis of SARS-CoV-2 receptor ACE2 expression in multiple solid tumors and matched non-diseased tissues. Infect Genet Evol : J Mol Epidemiol Evol Gen Infect Dis. 2020;85:104428. https:\/\/doi.org\/10.1016\/j.meegid.2020.104428.","journal-title":"Infect Genet Evol : J Mol Epidemiol Evol Gen Infect Dis"},{"key":"467_CR46","doi-asserted-by":"publisher","unstructured":"Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020. https:\/\/doi.org\/10.1016\/j.bbrc.2020.02.071.","DOI":"10.1016\/j.bbrc.2020.02.071"},{"issue":"4","key":"467_CR47","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.idc.2019.07.001","volume":"33","author":"DSC Hui","year":"2019","unstructured":"Hui DSC, Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin N Am. 2019;33(4):869\u201389. https:\/\/doi.org\/10.1016\/j.idc.2019.07.001.","journal-title":"Infect Dis Clin N Am"},{"issue":"10","key":"467_CR48","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMoa2001191","volume":"382","author":"ML Holshue","year":"2020","unstructured":"Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2001191.","journal-title":"N Engl J Med"},{"issue":"8","key":"467_CR49","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.3390\/jcm9082506","volume":"9","author":"I Gagliardi","year":"2020","unstructured":"Gagliardi I, Patella G, Michael A, Serra R, Provenzano M, Andreucci M. COVID-19 and the kidney: from epidemiology to clinical practice. J Clin Med. 2020;9(8):2506. https:\/\/doi.org\/10.3390\/jcm9082506.","journal-title":"J Clin Med"},{"issue":"5","key":"467_CR50","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/j.ackd.2020.09.003","volume":"27","author":"JH Ng","year":"2020","unstructured":"Ng JH, Bijol V, Sparks MA, Sise ME, Izzedine H, Jhaveri KD. Pathophysiology and pathology of acute kidney injury in patients with COVID-19. Adv Chronic Kidney Dis. 2020;27(5):365\u201376. https:\/\/doi.org\/10.1053\/j.ackd.2020.09.003.","journal-title":"Adv Chronic Kidney Dis"},{"key":"467_CR51","doi-asserted-by":"publisher","unstructured":"Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020. https:\/\/doi.org\/10.1038\/s41423-020-0400-4.","DOI":"10.1038\/s41423-020-0400-4"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-021-00467-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-021-00467-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-021-00467-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T10:21:47Z","timestamp":1637144507000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-021-00467-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1007\/s11357-021-00467-2","relation":{},"ISSN":["2509-2715","2509-2723"],"issn-type":[{"value":"2509-2715","type":"print"},{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"8 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. T\u00f3th, Fagyas, \u00c9des and Papp have a patent EP2664920A1 issued.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}